• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IDH 野生型老年胶质母细胞瘤患者的分子特征和临床结局:关西网络队列中老年病例与年轻病例的比较研究。

Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort.

机构信息

Department of Neurological Surgery, Wakayama Medical University School of Medicine, Kimiidera 811-1, Wakayama, 641-0012, Japan.

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.

出版信息

Brain Tumor Pathol. 2020 Apr;37(2):50-59. doi: 10.1007/s10014-020-00363-1. Epub 2020 May 2.

DOI:10.1007/s10014-020-00363-1
PMID:32361941
Abstract

Aging is a known negative prognostic factor in glioblastomas (GBM). Whether particular genetic backgrounds are a factor in poor outcomes of elderly patients with GBM warrants investigation. We aim to elucidate any differences between older and younger adult patients with IDH-wildtype GBM regarding both molecular characteristics and clinical outcomes. We collected adult cases diagnosed with IDH-wildtype GBM from the Kansai Network. Clinical and pathological characteristics were analyzed retrospectively and compared between older (≥ 70 years) and younger (≤ 50 years) cases. Included were 92 older vs. 33 younger cases. The older group included more patients with preoperative Karnofsky performance status score < 70 and had a shorter survival time than the younger group. MGMT promoter was methylated more frequently in the older group. TERT promoter mutation was more common in the older group. There were significant differences in DNA copy-number alteration profiles between age groups in PTEN deletion and CDK4 amplification/gain. In the older group, no molecular markers were identified, but surgical resection was an independent prognostic factor. Age-specific survival difference was significant in the MGMT methylated and TERT wildtype subgroup. Elderly patients have several potential factors in poor prognosis of glioblastomas. Varying molecular profiles may explain differing rates of survival between generations.

摘要

衰老在胶质母细胞瘤(GBM)中是一个已知的预后不良因素。特定的遗传背景是否是老年 GBM 患者预后不良的一个因素值得研究。我们旨在阐明 IDH 野生型 GBM 中年龄较大和年龄较小的成年患者之间在分子特征和临床结果方面的任何差异。我们从关西网络中收集了 IDH 野生型 GBM 的成年病例。回顾性分析了临床和病理特征,并比较了年龄较大(≥70 岁)和年龄较小(≤50 岁)患者之间的差异。包括 92 例年龄较大的患者和 33 例年龄较小的患者。年龄较大的组中术前 Karnofsky 表现状态评分<70 的患者更多,并且比年龄较小的组存活时间更短。MGMT 启动子在年龄较大的组中甲基化更为常见。TERT 启动子突变在年龄较大的组中更为常见。在 PTEN 缺失和 CDK4 扩增/增益方面,年龄组之间的 DNA 拷贝数改变谱存在显著差异。在年龄较大的组中,没有鉴定出分子标志物,但手术切除是独立的预后因素。在 MGMT 甲基化和 TERT 野生型亚组中,年龄特异性生存差异显著。老年患者在胶质母细胞瘤的预后不良方面有几个潜在的因素。不同的分子谱可能解释了不同代际之间的生存率差异。

相似文献

1
Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort.IDH 野生型老年胶质母细胞瘤患者的分子特征和临床结局:关西网络队列中老年病例与年轻病例的比较研究。
Brain Tumor Pathol. 2020 Apr;37(2):50-59. doi: 10.1007/s10014-020-00363-1. Epub 2020 May 2.
2
Predictive value of MGMT promoter methylation on the survival of TMZ treated -mutant glioblastoma.MGMT 启动子甲基化对替莫唑胺治疗的突变型胶质母细胞瘤患者生存的预测价值。
Cancer Biol Med. 2021 Feb 15;18(1):272-282. doi: 10.20892/j.issn.2095-3941.2020.0179.
3
Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.在未甲基化 MGMT 伴 IDH 野生型胶质母细胞瘤患者中,部分切除术比活检提供了整体生存获益。
Surg Oncol. 2020 Dec;35:515-519. doi: 10.1016/j.suronc.2020.10.016. Epub 2020 Nov 1.
4
Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.通过对 2016 年 WHO 弥漫性胶质瘤分类进行以下四项指标的细化:EGFR 扩增、TERT 突变、PTEN 缺失和 MGMT 甲基化,获得的临床见解。
BMC Cancer. 2019 Oct 17;19(1):968. doi: 10.1186/s12885-019-6177-0.
5
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.CDKN2A 纯合缺失联合甲基化 MGMT 状态对 IDH 野生型胶质母细胞瘤的临床意义。
Cancer Med. 2021 May;10(10):3177-3187. doi: 10.1002/cam4.3860. Epub 2021 Apr 10.
6
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study.MGMT 甲基化及其在不可切除 IDH 野生型胶质母细胞瘤中的预后意义:MGMT-GBM 研究。
Acta Neurochir (Wien). 2024 Oct 5;166(1):394. doi: 10.1007/s00701-024-06300-x.
7
Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors.老年弥漫性神经胶质瘤患者的特征和结局:一项由关西中枢神经系统肿瘤分子诊断网络进行的多机构队列研究。
J Neurooncol. 2018 Nov;140(2):329-339. doi: 10.1007/s11060-018-2957-7. Epub 2018 Aug 3.
8
Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.低 MGMT 表达与 IDH1 野生型胶质母细胞瘤接受替莫唑胺治疗后的更好结局相关。
J Neurooncol. 2021 Jan;151(2):135-144. doi: 10.1007/s11060-020-03675-6. Epub 2021 Jan 5.
9
Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.动脉自旋标记灌注加权成像有助于预测胶质母细胞瘤的分子生物标志物和生存。
Eur Radiol. 2020 Feb;30(2):1202-1211. doi: 10.1007/s00330-019-06379-2. Epub 2019 Aug 29.
10
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.根据 MGMT 启动子甲基化情况,对 IDH 野生型胶质母细胞瘤的分子差异进行研究。
Neuro Oncol. 2018 Feb 19;20(3):367-379. doi: 10.1093/neuonc/nox160.

引用本文的文献

1
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).利用两项随机试验(GEINO1401/EX-TEM)的数据探索老年胶质母细胞瘤患者的管理和结局。
J Neurooncol. 2024 Jun;168(2):299-306. doi: 10.1007/s11060-024-04668-5. Epub 2024 Apr 17.
2
'Slicing' glioblastoma drivers with the Swiss cheese model.用瑞士奶酪模型“切片”脑胶质母细胞瘤的驱动基因。
Trends Cancer. 2024 Jan;10(1):15-27. doi: 10.1016/j.trecan.2023.08.002. Epub 2023 Aug 23.
3
Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma.
IDH野生型胶质母细胞瘤老年患者的预后分析与列线图构建
Heliyon. 2023 Jul 17;9(7):e18310. doi: 10.1016/j.heliyon.2023.e18310. eCollection 2023 Jul.
4
Characteristic analysis and identification of novel molecular biomarkers in elderly glioblastoma patients using the 2021 WHO Classification of Central Nervous System Tumors.利用2021年世界卫生组织中枢神经系统肿瘤分类对老年胶质母细胞瘤患者新型分子生物标志物进行特征分析与鉴定
Front Neurosci. 2023 Jun 9;17:1165823. doi: 10.3389/fnins.2023.1165823. eCollection 2023.
5
Optimal managements of elderly patients with glioblastoma.老年胶质母细胞瘤患者的最佳治疗方案。
Jpn J Clin Oncol. 2022 Aug 5;52(8):833-842. doi: 10.1093/jjco/hyac075.
6
Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects.老年胶质母细胞瘤:分子与治疗方面的综述
Biomedicines. 2022 Mar 10;10(3):644. doi: 10.3390/biomedicines10030644.
7
Newly Diagnosed Glioblastoma in Elderly Patients.老年新发胶质母细胞瘤。
Curr Oncol Rep. 2022 Mar;24(3):325-334. doi: 10.1007/s11912-022-01201-7. Epub 2022 Feb 5.
8
Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas.TERT 启动子突变在成人弥漫性胶质瘤中的预后意义。
Brain Tumor Pathol. 2022 Jul;39(3):121-129. doi: 10.1007/s10014-021-00424-z. Epub 2022 Jan 31.
9
Genomic and molecular features distinguish young adult cancer from later-onset cancer.基因组和分子特征可区分青年期癌症与晚发性癌症。
Cell Rep. 2021 Nov 16;37(7):110005. doi: 10.1016/j.celrep.2021.110005.
10
Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.根据 2021 年世界卫生组织中枢神经系统肿瘤分类对成人弥漫性胶质瘤进行分级。
Lab Invest. 2022 Feb;102(2):126-133. doi: 10.1038/s41374-021-00667-6. Epub 2021 Sep 9.